ÂÜŔňÂŇÂ×

Prior to joining the Variantyx Board of Directors in late 2021, David Margulies, M.D. founded, co-founded, and participated as a Director and Senior Executive of a number of companies in the clinical computing, molecular diagnostics, and biotechnology fields. In the early 1980s, he co-founded and led BRS Medical, later acquired by WB Saunders and, ultimately, Elsevier North Holland. In the mid-1980s, while CIO at Boston Children’s Hospital, he led the design of software that was acquired by Cerner to be the basis of Cerner’s EMR. He became EVP, Chief Scientist, and a BOD member at Cerner in 1990. In 1996, he co-founded and was a Director of CareInsite, later acquired by WebMD in 2000. In 2000, he became co-founder, CEO, and Chairman of Correlagen Diagnostics, which was acquired by LabCorp in 2011 to be its genomic center of excellence. Dr. Margulies returned to Boston Children’s Hospital in 2011 as VP of Strategy and led the development of the institution’s genomic medicine strategy. In 2013, he co-founded and was Chairman of Q-State Biosciences, a Cambridge-based biotechnology company. Over the years, Dr. Margulies has served on numerous other public and private boards including D2 Hawkeye (acquired by Verisk), ObMedical (acquired by Philips), Circulation (acquired by Logisticare), Generation Health (acquired by CVS), Claritas Genomics (acquired by Q-State Biosciences), Travera, and Commonwealth Care Alliance. Dr. Margulies received his B.A. from Amherst College and his M.D. from Harvard Medical School. He completed his clinical training and board certification in Internal Medicine at Columbia College of Physicians and Surgeons. Dr. Margulies recently retired from the faculties of Genetics and Bioinformatics at the Harvard Medical School.